联合检测血清中ADA、GGT和AFU对肝癌患者诊断的临床意义

Predictive value of combined detection of serum ADA,GGT,and AFU in diagnosis of hepatocarcinoma

目的:检测腺苷脱氨酶(ADA)、γ谷氨酰转移酶(GGT)和α-L-岩藻糖苷酶(AFU)在肝癌患者血清中的含量,探讨其联合检测的意义。方法:本实验以76例肝癌患者的血清标本作为A组,选取76例肝硬化患者作为B组,选取76例肝炎患者作为C组,选取76例健康体检成人作为D组,检测四组血清中ADA、GGT和AFU的含量,分析ADA、GGT和AFU在肝癌患者不同临床病理特征之间的关系。结果:ADA、GGT和AFU在肝炎、肝硬化、肝癌患者血清中的含量依次增高,A组与其它组比较有统计学意义;且ADA、GGT和AFU的含量与肝癌的肿物体积及临床分期呈正相关性。结论:联合检测ADA、GGT和AFU在肝癌患者血清中含量明显增高,在肝癌发生、发展中具有重要作用。

Objective：To detect the serum levels of adenosine deaminase（ADA）,γ glutamyl transferase（GGT） and α-L-fucosidase（AFU） hepatocarcinoma patients to explore its predictive value in the diagnosis of hepatocarcinoma.Methods：Blood samples of hepatocarcinoma cases（group A,n=76）,liver cirrhosis patients（group B,n=76）,hepatitis patients（group C,n=76） andcontrol healthy volunteers（group D,n=76） were collected and detected for the ADA,GGT and AFu levels in order to explore the correlation between these parameters and pathological characters of different live diseases.Results：Levels of ADA,GGT,and AFU was significant higher in hepatocarcinoma patients than that in hepatitis or cirrhosis patients,of the latter two,levels in cirrhosis patients was higher.Levels of ADA,GGT and AFU were positively correlated to the size and stage of the tumor for patients with hepatocarcinoma.Conclusions：Combined detection of ADA,GGT,and AFU levels probably can predict the onset and progress of hepatocarcinoma.